FDA approved Samsung Bioepis’s Renflexis® (SB2, infliximab-abda) on Friday, April 21, 2017. Renflexis® is the fifth biosimilar...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
BiosimilarsIP.com News section provides updates on current news and events related to biologics and biosimilars.
-
-
On March 31, 2017, Celltrion, Inc. (“Celltrion”) filed three new petition for inter partes review (“IPR”) of two additional patents...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Pfizer, Inc. (“Pfizer”) filed a new petition with the Patent Trial and Appeal Board (“PTAB”) on March 24, 2017, for inter partes...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
We reported last week that Sanofi-Aventis U.S. LLC, Genzyme Corporation, and Regeneron Pharmaceuticals, Inc. had filed suit in...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Amgen’s Amgevita, an adalimumab biosimilar to AbbVie’s Humira®, received approval from the European Commission on March 23, 2017. ...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On March 21, 2017, Celltrion, Inc. (“Celltrion”) filed two new petitions for inter partes review (“IPR”) of U.S. Patent Nos....
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Hospira, Inc. (“Hospira”) filed a petition with the Patent Trial and Appeal Board (“PTAB”) on September 9, 2016, for inter partes...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]